175 related articles for article (PubMed ID: 33658478)
1. Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis.
Alssema M; Ruijgrok C; Blaak EE; Egli L; Dussort P; Vinoy S; Dekker JM; Denise Robertson M
Nutr Diabetes; 2021 Mar; 11(1):11. PubMed ID: 33658478
[TBL] [Abstract][Full Text] [Related]
2. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
[TBL] [Abstract][Full Text] [Related]
3. Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Hariya N; Mochizuki K; Inoue S; Saito M; Fuchigami M; Goda T; Osonoi T
Drugs R D; 2014 Sep; 14(3):177-84. PubMed ID: 25079671
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
[TBL] [Abstract][Full Text] [Related]
5. Reducing postprandial glucose in dietary intervention studies and the magnitude of the effect on diabetes-related risk factors: a systematic review and meta-analysis.
Ruijgrok C; Blaak EE; Egli L; Dussort P; Vinoy S; Rauh SP; Beulens JW; Robertson MD; Alssema M
Eur J Nutr; 2021 Feb; 60(1):259-273. PubMed ID: 32277270
[TBL] [Abstract][Full Text] [Related]
6. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Pharmacother; 2019 Dec; 20(18):2229-2235. PubMed ID: 31593486
[No Abstract] [Full Text] [Related]
7. Acute glycemic and insulinemic effects of low-energy sweeteners: a systematic review and meta-analysis of randomized controlled trials.
Greyling A; Appleton KM; Raben A; Mela DJ
Am J Clin Nutr; 2020 Oct; 112(4):1002-1014. PubMed ID: 32672338
[TBL] [Abstract][Full Text] [Related]
8. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Scheen AJ
Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
[TBL] [Abstract][Full Text] [Related]
10. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
11. The Rate of Glucose Appearance Is Related to Postprandial Glucose and Insulin Responses in Adults: A Systematic Review and Meta-analysis of Stable Isotope Studies.
Boers HM; Alssema M; Mela DJ; Peters HPF; Vonk RJ; Priebe MG
J Nutr; 2019 Nov; 149(11):1896-1903. PubMed ID: 31291451
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones.
Aoki K; Sato H; Terauchi Y
Endocr J; 2019 May; 66(5):395-401. PubMed ID: 31019154
[TBL] [Abstract][Full Text] [Related]
13. Drug therapy of postprandial hyperglycaemia.
Mooradian AD; Thurman JE
Drugs; 1999 Jan; 57(1):19-29. PubMed ID: 9951949
[TBL] [Abstract][Full Text] [Related]
14. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Tsujino D; Nishimura R; Taki K; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2011 Mar; 13(3):303-8. PubMed ID: 21291335
[TBL] [Abstract][Full Text] [Related]
15. Miglitol, a new alpha-glucosidase inhibitor.
Sels JP; Huijberts MS; Wolffenbuttel BH
Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
Reuser AJ; Wisselaar HA
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():19-24. PubMed ID: 8001622
[TBL] [Abstract][Full Text] [Related]
17. Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Dash RP; Babu RJ; Srinivas NR
Xenobiotica; 2018 Jan; 48(1):89-108. PubMed ID: 28010166
[TBL] [Abstract][Full Text] [Related]
18. Acarbose, the α-glucosidase inhibitor, attenuates the blood pressure and splanchnic blood flow responses to meal in elderly patients with postprandial hypotension concomitant with abnormal glucose metabolism.
Qiao W; Li J; Li Y; Qian D; Chen L; Wei X; Jin J; Wang Y
Blood Press Monit; 2016 Feb; 21(1):38-42. PubMed ID: 26474001
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.
Joshi SR; Standl E; Tong N; Shah P; Kalra S; Rathod R
Expert Opin Pharmacother; 2015; 16(13):1959-81. PubMed ID: 26255950
[TBL] [Abstract][Full Text] [Related]
20. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
